Essential Thrombocythemia Clinical Trials in Boston, Massachusetts
3 recruitingBoston, Massachusetts
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Ajax Therapeutics, Inc.76 enrolled21 locationsNCT06343805
Recruiting
Phase 2
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Polycythemia VeraEssential Thrombocythemia
Massachusetts General Hospital60 enrolled4 locationsNCT04644211